Overview

Tralokinumab Administered With Device A in Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2023-01-26
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection with Device A in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).
Phase:
Phase 3
Details
Lead Sponsor:
LEO Pharma